Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis.
暂无分享,去创建一个
J P Luzio | R. Simari | M. Bennett | J. Luzio | K. Macdonald | S. Chan | P. Weissberg | M Bennett | K Macdonald | S W Chan | R Simari | P Weissberg | S. W. Chan | Shiu-Wan Chan
[1] S. Yonehara,et al. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.
[2] S. Lowe,et al. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene‐mediated apoptosis. , 1996, The EMBO journal.
[3] K. Kinzler,et al. A model for p53-induced apoptosis , 1997, Nature.
[4] J. Lippincott-Schwartz,et al. Brefeldin A: insights into the control of membrane traffic and organelle structure , 1992, The Journal of cell biology.
[5] Ladinsky Ms,et al. The trans-Golgi network can be dissected structurally and functionally from the cisternae of the Golgi complex by brefeldin A. , 1992 .
[6] R. Black,et al. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme , 1992, Cell.
[7] N. Copeland,et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.
[8] Atsushi Hase,et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.
[9] R Montesano,et al. Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.
[10] D. Vaux,et al. CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO‐1)‐transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease. , 1996, The EMBO journal.
[11] Arul M. Chinnaiyan,et al. FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.
[12] N. Hay,et al. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. , 1994, Genes & development.
[13] E. Nabel,et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. , 1994, Science.
[14] T. Littlewood,et al. Increased sensitivity of human vascular smooth muscle cells from atherosclerotic plaques to p53-mediated apoptosis. , 1997, Circulation research.
[15] G. Evan,et al. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. , 1995, Nucleic acids research.
[16] M. Oren,et al. Specific loss of apoptotic but not cell‐cycle arrest function in a human tumor derived p53 mutant. , 1996, The EMBO journal.
[17] M. Karin,et al. p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes , 1994, Nature.
[18] A. Levine,et al. Essential role for p53-mediated transcription in E1A-induced apoptosis. , 1995, Genes & development.
[19] T. Soussi,et al. Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. , 1994, The EMBO journal.
[20] G. Evan,et al. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. , 1997, Science.
[21] D. Israeli,et al. A novel p53‐inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis , 1997, The EMBO journal.
[22] John Calvin Reed,et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.
[23] E. Shaulian,et al. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. , 1995, Genes & development.
[24] S. Velasco-Miguel,et al. Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.
[25] N. Jenkins,et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.
[26] E. May,et al. Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. , 1995, Oncogene.
[27] S. Friend,et al. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. , 1995, Oncogene.
[28] E. Shaulian,et al. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.